Central Line-Associated Mucor velutinosus Bloodstream Infection in an Immunocompetent Pediatric Patient

Madan Kumar1, Barbara Jantausch1, Clarivet Torres2

  • 1Pediatric Infectious Diseases, Microbiology Children's National Medical Center.

Insights

This case study details the first reported instance of Mucor velutinosus bloodstream infection in a pediatric patient without cancer. The child recovered after treatment with amphotericin B and central line removal.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pediatrics

Background:

  • Mucor velutinosus is a fungus rarely implicated in human infections.
  • Central venous catheters, such as Broviac catheters, are potential sources of fungal bloodstream infections in immunocompromised patients.
  • Pediatric patients with intestinal failure often require long-term central venous access and parenteral nutrition, increasing infection risk.

Observation:

  • A 6-year-old boy with intestinal failure experienced a bloodstream infection and wound infection at the Broviac catheter insertion site.
  • Microscopic examination revealed characteristic fungal elements, including wide nonseptate hyphae, sporangiophores, columella, and chlamydospores.
  • Identification was confirmed as Mucor velutinosus via mass spectrometry and genomic sequencing.

Findings:

  • The patient presented with a bloodstream infection caused by Mucor velutinosus, a rare pathogen in this context.
  • This represents the first documented case of Mucor velutinosus bloodstream infection in a pediatric patient without a cancer diagnosis.
  • Successful treatment involved intravenous amphotericin B and removal of the infected central venous catheter.

Implications:

  • Highlights the potential for Mucor velutinosus to cause serious infections in vulnerable pediatric populations.
  • Emphasizes the importance of considering rare fungal pathogens in bloodstream infections, especially in patients with central lines.
  • Underscores the need for prompt diagnosis and appropriate antifungal therapy, alongside device removal, for successful management.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
279
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
251
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
316
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1000
The Central Dogma01:25

The Central Dogma

Overview
140.1K